Your browser doesn't support javascript.
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England.
Krutikov, Maria; Palmer, Tom; Tut, Gokhan; Fuller, Christopher; Azmi, Borscha; Giddings, Rebecca; Shrotri, Madhumita; Kaur, Nayandeep; Sylla, Panagiota; Lancaster, Tara; Irwin-Singer, Aidan; Hayward, Andrew; Moss, Paul; Copas, Andrew; Shallcross, Laura.
  • Krutikov M; UCL Institute of Health Informatics, London, UK.
  • Palmer T; UCL Institute for Global Health, London, UK.
  • Tut G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Fuller C; UCL Institute of Health Informatics, London, UK.
  • Azmi B; UCL Institute of Health Informatics, London, UK.
  • Giddings R; UCL Institute of Health Informatics, London, UK.
  • Shrotri M; UCL Institute of Health Informatics, London, UK.
  • Kaur N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Sylla P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Lancaster T; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Irwin-Singer A; Department of Health and Social Care, London, UK.
  • Hayward A; UCL Institute of Epidemiology & Health Care, London, UK.
  • Moss P; Health Data Research, London, UK.
  • Copas A; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Shallcross L; UCL Institute for Global Health, London, UK.
Lancet Healthy Longev ; 3(1): e13-e21, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1665611
ABSTRACT

Background:

Long-term care facilities (LTCFs) have reported high SARS-CoV-2 infection rates and related mortality, but the proportion of infected people among those who have survived, and duration of the antibody response to natural infection, is unknown. We determined the prevalence and stability of nucleocapsid antibodies (the standard assay for detection of previous infection) in staff and residents in LTCFs in England.

Methods:

This was a prospective cohort study of residents 65 years or older and of staff 65 years or younger in 201 LTCFs in England between March 1, 2020, and May 7, 2021. Participants were linked to a unique pseudo-identifier based on their UK National Health Service identification number. Serial blood samples were tested for IgG antibodies against SARS-CoV-2 nucleocapsid protein using the Abbott ARCHITECT i-system (Abbott, Maidenhead, UK) immunoassay. Primary endpoints were prevalence and cumulative incidence of antibody positivity, which were weighted to the LTCF population. Incidence rate of loss of antibodies (seroreversion) was estimated from Kaplan-Meier curves.

Findings:

9488 samples were included, 8636 (91·0%) of which could be individually linked to 1434 residents and 3288 staff members. The cumulative incidence of nucleocapsid seropositivity was 34·6% (29·6-40·0) in residents and 26·1% (23·0-29·5) in staff over 11 months. 239 (38·6%) residents and 503 women (81·3%) were included in the antibody-waning analysis, and median follow-up was 149 days (IQR 107-169). The incidence rate of seroreversion was 2·1 per 1000 person-days at risk, and median time to reversion was 242·5 days.

Interpretation:

At least a quarter of staff and a third of surviving residents were infected with SAR-CoV-2 during the first two waves of the pandemic in England. Nucleocapsid-specific antibodies often become undetectable within the first year following infection, which is likely to lead to marked underestimation of the true proportion of people with previous infection. Given that natural infection might act to boost vaccine responses, better assays to identify natural infection should be developed.

Funding:

UK Government Department of Health and Social Care.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Observational study / Prevalence study / Prognostic study / Risk factors Language: English Journal: Lancet Healthy Longev Year: 2022 Document Type: Article Affiliation country: S2666-7568(21)00282-8

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Observational study / Prevalence study / Prognostic study / Risk factors Language: English Journal: Lancet Healthy Longev Year: 2022 Document Type: Article Affiliation country: S2666-7568(21)00282-8